Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Argenx SE
  6. News
  7. Summary
    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

argenx : UBS Starts argenx at Buy with $390 Price Target

06/18/2021 | 09:02am EDT


ę MT Newswires 2021
All news about ARGENX SE
07/23DGAP-NEWS : Il settore delle biotecnologie -2-
DJ
07/23DGAP-NEWS : Il settore delle biotecnologie archivia un secondo trimestre all'ins..
DJ
07/23PRESS RELEASE : Solid second quarter for the -2-
DJ
07/22ANALYST RECOMMENDATIONS : Barclays, Chevron, Flutter, Netflix, Unilever...
07/22ARGENX : Wedbush Adjusts Price Target on Argenx to $362 From $344 on Efgartigimo..
MT
07/22ARGENX : argenx to Report Half Year 2021 Financial Results and Second Quarter Bu..
PU
07/22argenx to Report Half Year 2021 Financial Results and Second Quarter Business..
GL
07/22ARGENX : to Report Half Year 2021 Financial Results and Second Quarter Business ..
AQ
07/20European ADRs Up 0.5% Tuesday
MT
07/20ANALYST RECOMMENDATIONS : Deliveroo, IBM, Intercontinental Hotels, LivaNova, Via..
More news
Financials
Sales 2021 174 M 205 M 205 M
Net income 2021 -600 M -707 M -707 M
Net cash 2021 1 463 M 1 723 M 1 723 M
P/E ratio 2021 -23,1x
Yield 2021 -
Capitalization 13 745 M 16 168 M 16 188 M
EV / Sales 2021 70,6x
EV / Sales 2022 66,3x
Nbr of Employees 336
Free-Float 99,0%
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 267,90 €
Average target price 284,29 €
Spread / Average Target 6,12%
EPS Revisions
Managers and Directors
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Eric Castaldi Chief Financial Officer
Peter K. M. Verhaeghe Chairman
Hans J. W. de Haard Chief Scientific Officer
Wim Parys Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ARGENX SE10.70%16 311
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308